RBC Capital Maintains Sector Perform on Alkermes, Raises Price Target to $40
Earnings Call Summary | Alkermes(ALKS.US) Q1 2025 Earnings Conference
Alks Outlines 2025 Growth With $320M-$340M LYBALVI Sales Target and Key ALKS 2680 Data Milestones
Alkermes Shares Are Trading Higher After the Company Reported Q1 Financial Results and Beat Its EPS and Revenue Estimates.
Alkermes GAAP EPS of $0.13 Beats by $0.08, Revenue of $306.5M Beats by $2.39M
Earnings Scheduled For May 1, 2025
Here's the Major Earnings Before the Open Tomorrow
NRx Pharma Announces Grant Of Filing Fee Waiver By FDA To Exempt NRx From $4.3M Fee To File New Drug Application For NRX-100
Earnings Call Summary | Sage Therapeutics(SAGE.US) Q1 2025 Earnings Conference
Sage Therapeutics Q1 EPS $(1.01) Misses $(0.99) Estimate, Sales $14.06M Inline
Here Are the Major Earnings After the Close Today
Amazon.com To $253? Here Are 10 Top Analyst Forecasts For Tuesday
Earnings Scheduled For April 29, 2025
Beyond The Numbers: 6 Analysts Discuss Alkermes Stock
What to Expect From Sage Therapeutics's Earnings
Expert Outlook: Sage Therapeutics Through The Eyes Of 4 Analysts
Needham Reiterates Hold on Sage Therapeuticsto Hold
Sage Therapeutics Analyst Ratings
Executive Reshuffles: CAT, LMT, and APA
AI replacing animal experiments? A message from the FDA has left "monkey breeders" feeling devastated, and experts state that "we are still far from the stage of implementation."
① The news that the USA FDA has publicly stated it will gradually replace animal testing requirements has led to an increase in the stock prices of AI pharmaceutical companies, impacting traditional drug evaluation CRO companies; ② Some believe this action represents a trend in Industry development. However, others believe that it is far from being implementable.